Everand Logo

Welcome to Everand!

  • STAT

    In a surprise, Hans Bishop takes over as CEO of Grail, the liquid biopsy startup

    Grail, the San Francisco company trying to develop a blood test to detect cancer, said it had appointed Hans Bishop, previously the CEO of Juno Therapeutics, as its new CEO
    by Matthew Herper Jun 06, 2019 3 minutes

    Grail, the San Francisco company that has raised $1.6 billion to develop a blood test to detect cancer, announced Thursday that it had appointed Hans Bishop, previously the CEO of Juno Therapeutics, as its new chief executive.

    Bishop, who led Juno until it was sold to Celgene for $9 billion in March 2018, will be the third chief executive Grail has had since it was founded in 2015. He will replace

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT1 min read
    Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
    To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
    A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
    Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

    Related Books & Audiobooks